JLK (CEO Dongmin Kim) , a medical artificial intelligence (AI) specialist company, announced that it will participate in the International Stroke Conference 2026 (ISC 2026), which will be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA from February 4th to 6th.
The International Stroke Conference (ISC) is the world's largest professional stroke conference, bringing together stroke physicians, researchers, and policymakers from around the world. It is recognized as a hub for global standards discussion, sharing the latest treatment guidelines, clinical research, and emerging technology trends. Hosted by the American Heart Association (AHA), the ISC has significant influence on clinical practice, policy, and industry, and serves as a key contact point for major U.S. hospitals and global medical device companies seeking new technology adoption and partnerships.
Through its participation in ISC 2026, JLK plans to showcase its portfolio of AI solutions supporting stroke diagnosis and treatment decision-making to global medical professionals and industry stakeholders. It also plans to engage in adoption discussions with US healthcare institutions and medical device companies, focusing on clinical usability and workflow improvements. Beyond simply promoting its technology, the company aims to present a stroke AI utilization model optimized for the US healthcare system and discuss potential collaborations with major hospitals and potential partners.
During the conference, Professor Lance J. Lee, who established a specialized distribution company to sell and commercialize JLK solutions in the US, will present on AI solutions. Professor Lee, a former professor of neurology at UCLA School of Medicine and currently director of the Stroke Center at Adventist Health Glendale Hospital, is recognized as an expert with both clinical experience and experience in commercializing medical AI. The presentation will comprehensively highlight the clinical effectiveness of JLK AI solutions, their applicability in real-world medical settings, and their potential for business expansion, including adoption in US medical institutions.
The company expects this announcement to bolster JLK Solutions' credibility by demonstrating proven clinical efficacy and justification for adoption from the perspective of US medical professionals. Furthermore, the presentation, delivered by experts who have directly established and operated distribution structures in the US, is expected to have a positive impact on discussions with major local hospitals and global medical device companies.
Kim Dong-min, CEO of JLK, said, “ISC is the most influential academic stage connecting clinical, policy, and industry in the field of stroke,” and added, “Participation in ISC 2026 and Professor Lance J. Lee’s presentation will be a turning point for JLK’s stroke AI solution to be recognized for both clinical trust and business competitiveness from major U.S. hospitals and global partners.”
- See more related articles
You must be logged in to post a comment.